Aqueous, oil, and ointment formulations of ketorolac: Efficacy against prostaglandin E2-induced ocular inflammation and safety: A technical note

AAPS PharmSciTech

Volumn 7, Issue 4, 2006, Pages

  Malhotra, Manjusha ^a   Majumdar, Dipak K ^b  

^a DELHI INSTITUTE OF PHARMACEUTICAL SCIENCES AND RESEARCH   (India)

^b UNIVERSITY OF DELHI   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BENZALKONIUM CHLORIDE; EDETATE DISODIUM; EYE DROPS; KETOROLAC TROMETAMOL; PROSTAGLANDIN E2; SESAME SEED OIL; SOYBEAN OIL; EXCIPIENT; KETOROLAC; OIL; WATER;

ANIMAL EXPERIMENT; ANIMAL MODEL; AQUEOUS SOLUTION; ARTICLE; BLINKING; CONTROLLED STUDY; DIGESTIVE SYSTEM ULCER; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; EYE INFLAMMATION; EYE PROTECTION; FEMALE; LACRIMAL FLUID; MALE; NEUTROPHIL CHEMOTAXIS; NEUTROPHIL COUNT; NONHUMAN; OINTMENT; PROTEIN TRANSPORT; RABBIT; RAT; TREATMENT DURATION; ANIMAL; CHEMICALLY INDUCED DISORDER; CHEMISTRY; METHODOLOGY; OSTEITIS; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; ANIMALS; DINOPROSTONE; DRUG COMPOUNDING; EXCIPIENTS; FEMALE; KETOROLAC; MALE; OILS; OINTMENTS; OSTEITIS; RABBITS; TREATMENT OUTCOME; WATER;

EID: 33847184606     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/pt070496     Document Type: Article

References (28)

1. Hall DWR, Jaitly KD. Inflammatory responses of the rabbit eye to prostaglandins. Agents Actions. 1977;2:123-133.
2. 1 and aqueous humor dynamics. Invest Ophthalmol. 1972;11:1022-1027.
3. Eakins KE. Prostaglandin and non-prostaglandin mediated breakdown of the blood-aqueous barrier. Exp Eye Res. 1977;25:483-498.
4. Srinivasan BD, Kulkarni PS. The role of arachidonic acid metabolites in the mediation of the polymorphonuclear leukocyte response following corneal injury. Invest Ophthalmol Vis Sci. 1980;19:1087-1093.
5. Berman MB, Barber JC, Talamo RC, Langley CE. Corneal ulceration and the serum antiproteases, I: alpha 1-antitrypsin. Invest Ophthalmol. 1973;12:759-770.
6. 4 on conjunctival vasopermeability and blood aqueous barrier integrity. Invest Ophthalmol Vis Sci. 1985;26:481-485.
7. Anderson JA, Leopold LH. Antiproteolytic activities found in human tears. Ophthalmology. 1981;88:82-84.
8. Rooks WH II, Tomolonis AJ, Maloney PJ, Wallach MB, Schuler ME. The analgesic and anti-inflammatory profile of (±)-5-benzoyl-1, 2-dihydro-3H-pyrrolo [1,2a] pyrrole-1-carboxylic acid (RS-37619). Agents Actions. 1982;12:684-690.
9. Flach AJ, Kraff MC, Sanders DR, Tanenbaum L. The quantitative effect of 0.5% ketorolac tromethamine solution and 0.1% dexamethasone sodium phosphate solution on post-surgical blood aqueous barrier. Arch Ophthalmol. 1988;106:480-483.
10. Heier J, Cheetham JK, Degryse R, et al. Ketorolac tromethamine 0.5% ophthalmic solution in the treatment of moderate to severe ocular inflammation after cataract surgery: a randomized, vehicle-controlled clinical trial. Am J Ophthalmol. 1999;127:253-259.
11. Solomon KD, Cheetham JK, Degryse R, Brint SF, Rosenthal A. Topical ketorolac tromethamine 0.5% ophthalmic solution in ocular inflammation after cataract surgery. Ophthalmology. 2001;108:331-337.
12. Fraser-Smith EB, Mathews TR. Effect of ketorolac on Candida albicans ocular infection in rabbit. Arch Ophthalmol. 1987;105:264-267.
13. Fraser-Smith EB, Mathews TR. Effect of ketorolac on Pseudomonas aeruginosa ocular infection in rabbits. J Ocul Pharmacol. 1988;4:101-109.
14. Price FW Jr, Price MO, Zeh W, Dobbins K. Pain reduction after laser in situ keratomileusis with ketorolac tromethamine ophthalmic solution 0.5%: a randomized, double-masked, placebo-controlled trial. J Refract Surg. 2002;18:140-144.
15. Mahoney JM, Waterbury LD. (±)-5-benzoyl-1, 2-dihydro-3H-pyrrolo [1,2a] pyrrole-1-carboxylic acid (RS-37619): a non-irritating ophthalmic anti-inflammatory agent. Invest Ophthalmol Vis Sci. 1983;24:151-159.
16. Malhotra M, Majumdar DK. Effect of preservative, antioxidant and viscolizing agents on in vitro transcorneal permeation of ketorolac tromethamine. Indian J Exp Biol. 2002;40: 555-559.
17. Malhotra M, Majumdar DK. In vitro transcorneal permeation of ketorolac from oil based ocular drops and ophthalmic ointment. Indian J Exp Biol. 1997;35:1324-1330.
18. Malhotra M, Majumdar DK. In vivo ocular availability of ketorolac following ocular instillations of aqueous, oil and ointment formulations to normal corneas of rabbits: a technical note. AAPS PharmSciTech. 2005;6:E523-E526.
19. Pharmacopoeia of India. 2nd ed. Delhi, India: Government of India, Ministry of Health and Family Welfare; 1970:203.
20. Abelson MB, Butrus SI, Kliman GH, Larson DL, Corey EJ, Smith LM. Topical arachidonic acid: a model for screening anti-inflammatory agents. J Ocul Pharmacol. 1987;3:63-74.
21. Sood R. Medical Laboratory Technology: Methods and Interpretations. 4th ed. New Delhi, India: Jaypee Brothers; 1999:169-237.
22. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193:265-275.
23. Singh S, Majumdar DK. Evaluation of anti-inflammatory activity of fatty acids of Ocimum sanctum fixed oil. Indian J Exp Biol. 1997;35:380-383.
24. Maurice DM, Mishima S. Ocular pharmacokinetics. In: Sears ML, ed. Handbook of Experimental Pharmacology:Pharmacology of the Eye. vol. 69. Berlin-Heildelberg, Germany: Springer-Verlag; 1984:19-103.
25. Rang HP, Dale MM, Ritter JM, Moore PK. Pharmacology. 5th ed. Edinburgh, Scotland: Churchill Livingstone; 2003:217-243.
26. Pillinger MH, Capodici C, Rosenthal P, et al. Modes of action of aspirin-like drugs: salicylates inhibit erk activation and integrin-dependent neutrophil adhesion. Proc Natl Acad Sci USA. 1998;95:14540-14545.
27. Katzung BG. Basic & Clinical Pharmacology. 9th ed. Boston, MA: McGraw-Hill; 2004:576-603.
28. Gibaldi M. Biopharmaceutics and Clinical Pharmacokinetics. 3rd ed. Philadelphia, PA: Lea & Febiger; 1984:85-112.